DHR logo

DHR Danaher Corp.

$226.60
$2.11
(0.94%)
Pre-Market
51

Neutral Sentiment

How do you feel about DHR?

Loading...
Danaher Schedules Third Quarter 2026 Earnings Conference Call
Danaher Schedules Third Quarter 2026 Earnings Conference Call Danaher Schedules Third Quarter 2026 Earnings Conference CallPR NewswireWASHINGTON, Sept. 22, 2026 WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings...
PR Newswire
Danaher Announces Quarterly Dividend
Danaher Announces Quarterly Dividend Danaher Announces Quarterly DividendPR NewswireWASHINGTON, Sept. 15, 2026 WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of...
PR Newswire
ELV or DHR: Which Is the Better Value Stock Right Now?
ELV vs. DHR: Which Stock Is the Better Value Option?
Zacks
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Zacks
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Danaher (DHR) Seen Deftly Navigating AI Integration
Danaher (DHR) Seen Deftly Navigating AI Integration...
Yahoo! Finance: News
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Insider Transaction: Rainer Blair Sells $12.74M Worth Of Danaher Shares
Making a noteworthy insider sell on August 24, Rainer Blair, President & CEO at Danaher (NYSE:DHR), is reported in the latest SEC filing. What Happened: Blair's decision to sell 58,255 shares of Danaher wasread more...
Benzinga
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Zacks